Galectin Therapeutics, Inc. (GALT)
-NasdaqCM | Prev Close: | 4.40 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 7.00 |
|---|
| Beta: | 2.03 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.60 - 5.22 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 92,681 |
|---|
| Market Cap: | 71.50M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.77 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- GALECTIN THERAPEUTICS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of ShareholdersPR Newswire(Wed, May 15)
- GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, May 15)
- Galectin Therapeutics Reports First Quarter 2013 Financial ResultsPR Newswire(Fri, May 10)
- GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Fri, May 10)
- GALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Generic Drug Pricing Pressure Remains in Western Europe, While Central and Eastern Europe, Latin America and Parts of Asia Eye Fairly Strong Growth in Generic DrugsWall Street Transcript(Thu, May 2)
- Galectin Therapeutics Gets A Bid After Promising Resultsat Seeking Alpha(Wed, May 1)
- 4 Healthcare Stock Stories To Kick Off the Trading Weekat Wall St. Cheat Sheet(Mon, Apr 29)
- Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical StudiesPR Newswire(Mon, Apr 29)
- GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Mon, Apr 29)
- RedChip TV Announces Guest Lineup for This Week's "RedChip Money Report"GlobeNewswire(Fri, Apr 19)
- 4 Healthcare Stock Stories for Thursday Investment Wellnessat Wall St. Cheat Sheet(Thu, Apr 18)
- 2 Biotech Stocks Announcing Key Early Stage Clinical Developmentsat Seeking Alpha(Wed, Apr 17)
- Galectin Therapeutics to Present New Data on the Treatment of Liver Fibrosis and CirrhosisPR Newswire(Wed, Apr 17)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.69 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.17 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis an...
View More 
0.80%